Long-Term Subconjunctival Delivery of Brimonidine Tartrate for Glaucoma Treatment Using a Microspheres/Carrier System

被引：21

作者：

Pek, Y. Shona ^{[1
]}

Wu, Hong ^{[1
]}

Mohamed, Siti Thaharah ^{[1
]}

Ying, Jackie Y. ^{[1
]}

机构：

[1] Inst Bioengn & Nanotechnol, 31 Biopolis Way, Singapore 138669, Singapore

来源：

ADVANCED HEALTHCARE MATERIALS | 2016年 / 5卷 / 21期

关键词：

animal models; controlled drug release; glaucoma; microspheres; OCULAR DRUG-DELIVERY; OPEN-ANGLE GLAUCOMA; CHYMOTRYPSIN-INDUCED GLAUCOMA; WALLED POLYMER MICROSPHERES; INTRAOCULAR-PRESSURE; SUSTAINED-RELEASE; IN-VITRO; PHARMACOKINETICS; HYPERTENSION; RABBITS;

D O I：

10.1002/adhm.201600780

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Core-shell polymer microspheres with poly(d,l-lactic-co-glycolic acid) core and poly(l-lactic acid) (PLLA) shell are developed for the long-term subconjunctival release of brimonidine tartrate (BT) in order to reduce intraocular pressure (IOP) in the treatment of glaucoma. The PLLA-rich shell acts as a diffusion barrier, enabling linear release of BT over an extended period of 40 d. The microspheres are encased in a porous non-degradable methacrylate-based carrier for ease of subconjunctival implantation in a glaucoma-induced rabbit model. In vivo release of BT from the microspheres/carrier system has enabled a significant, immediate IOP reduction of 20 mmHg, which is sustained for 55 d. Long-term IOP reduction may be maintained by periodic replacement of the microspheres/carrier system.

引用

页码：2823 / 2831

页数：9

共 43 条

[1] Brimonidine - A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension [J].

Adkins, JC ;

Balfour, JA .

DRUGS & AGING, 1998, 12 (03) :225-241

[2] Evaluation of a Prednisolone Acetate-Loaded Subconjunctival Implant for the Treatment of Recurrent Uveitis in a Rabbit Model [J].

Ang, Marcus ;

Ng, Xuwen ;

Wong, Cheewai ;

Yan, Peng ;

Chee, Soon-Phaik ;

Venkatraman, Subbu S. ;

Wong, Tina T. .

PLOS ONE, 2014, 9 (05)

[3] Brimonidine Tartrate-Eudragit Long-Acting Nanoparticles: Formulation, Optimization, In Vitro and In Vivo Evaluation [J].

Bhagav, Prakash ;

Upadhyay, Hariom ;

Chandran, Sajeev .

AAPS PHARMSCITECH, 2011, 12 (04) :1087-1101

[4] Biopharmaceutical considerations in topical ocular drug delivery [J].

Davies, NM .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2000, 27 (07) :558-562

[5] 28-day intraocular pressure reduction with a single dose of brimonidine tartrate-loaded microspheres [J].

Fedorchak, Morgan V. ;

Conner, Ian P. ;

Medina, Carlos A. ;

Wingard, Jeremy B. ;

Schuman, Joel S. ;

Little, Steven R. .

EXPERIMENTAL EYE RESEARCH, 2014, 125 :210-216

[6]

Ghate Deepta, 2006, Expert Opin Drug Deliv, V3, P275, DOI 10.1517/17425247.3.2.275

[7] Cell immobilization in gelatin-hydroxyphenylpropionic acid hydrogel fibers [J].

Hu, Min ;

Kurisawa, Motoichi ;

Deng, Rensheng ;

Teo, Choon-Meng ;

Schumacher, Annegret ;

Thong, Ya-Xuan ;

Wang, Lishan ;

Schumacher, Karl M. ;

Ying, Jackie Y. .

BIOMATERIALS, 2009, 30 (21) :3523-3531

[8] Physicochemical properties and in vivo assessment of timolol-loaded poly(D,L-lactide-co-glycolide) films for long-term Intraocular pressure lowering effects [J].

Huang, SF ;

Chen, JL ;

Yeh, MK ;

Chiang, CH .

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2005, 21 (06) :445-453

[9] Primary viscocanalostomy versus trabeculectomy in white patients with open-angle glaucoma - A randomized clinical trial [J].

Jonescu-Cuypers, CP ;

Jacobi, PC ;

Konen, W ;

Krieglstein, GK .

OPHTHALMOLOGY, 2001, 108 (02) :254-258

[10] Pharmacokinetics of topical ocular drug delivery: Potential uses for the treatment of diseases of the posterior segment and beyond [J].

Koevary, SB .

CURRENT DRUG METABOLISM, 2003, 4 (03) :213-222

← 1 2 3 4 5 →